News

RESI_Logo.PNG

December 7, 2021

Calendar_Logo.001.png

Summit Biomedical Imaging To Attend Digital RESI Meeting 

January 11 To January 13 , 2022

New York, NY -- Summit Biomedical Imaging ("Summit"), a cancer diagnostic company announced today that the company will attend the virtual Redefining Early Stage Investments ("RESI") Meeting from January 11 to January 13. (Link)

NCI_Logo.png

Summit Biomedical Imaging Awarded $1.5M NCI Phase II STTR Grant

New York, NY -- Summit Biomedical Imaging ("Summit"), a cancer diagnostic company announced today that the National Institute of Cancer ("NCI") of the National Institute of Health ("NIH") has awarded Summit approximately $1.5M over two years in a Phase II grant as part of the Small Business Technology Transfer ("STTR") program. 

August 19, 2021

Calendar_Logo.001.png
NCI_Logo.png

July 12, 2021

Calendar_Logo.001.png

Summit Biomedical Imaging Selected By NCI For NCI SBIR Investor Initiatives

New York, NY -- Summit Biomedical Imaging ("Summit"), a cancer diagnostic company announced today that the National Institute of Cancer ("NCI") of the National Institute of Health ("NIH") has selected Summit

as one of the showcase companies for the 2021-2022 NCI SBIR Investor initiatives. (Link)

EJNMMI_Logo.PNG

May 5, 2021

Calendar_Logo.001.png

Positive Data Published From A Phase I Study Of A PARP1-Targeted Topical Fluorophore For The Detection Of Oral Cancer

New York, NY -- Positive results from a phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer were published in the peer-reviewed journal of European Journal of Nuclear Medicine and Molecular Imaging. (Link)

Summit Biomedical Imaging Selected By NCI For TABA Needs Assessment

New York, NY -- Summit Biomedical Imaging ("Summit"), a cancer diagnostic company announced today that the National Institute of Cancer ("NCI") of the National Institute of Health ("NIH") has selected Summit to participate in the Technical and Business Assistance ("TABA") Needs Assessment program.

December 22, 2020

Calendar_Logo.001.png
NCI_Logo.png
NCI_Logo.png

Summit Biomedical Imaging Awarded $260k NCI Phase I STTR Grant

New York, NY -- Summit Biomedical Imaging ("Summit"), a cancer diagnostic company announced today that the National Institute of Cancer ("NCI") of the National Institute of Health ("NIH") has awarded Summit approximately $260k over one year in a Phase I grant as part of the Small Business Technology Transfer ("STTR") program. 

September 10, 2020

Calendar_Logo.001.png

Featured Publications

A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer (Link)

Paula Demétrio de Souza França, Susanne Kossatz, Christian Brand, et al. 

Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers (Link)

Susanne Kossatz, Giacomo Pirovano, Paula Demétrio de Souza França, et al. 

Nature Biomedical Engineering, 2020, 4, 272–285.

Fluorescence-guided resection of tumors in mouse models of oral cancer (Link)

Paula Demétrio de Souza França, Navjot Guru, Sheryl Roberts, et al. 

Scientific Reports, 2020, 10, 11175.

Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent (Link)

Susanne Kossatz, Christian Brand, Stanley Gutiontov, et al. 

Scientific Reports, 2016, 6, 21371. 

Archive

Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use (Link)

Molecular Imaging and Biology, 2022, in print

Paula Demétrio de Souza França, Tara Virar, Sheryl Roberts et al. 

Combined PARP1-targeted nuclear contrast and reflectance contrast enhances confocal microscopic detection of basal cell carcinoma (Link)

Journal of Nuclear Medicine, 2021, in print

Aditi Sahu, Jose Cordero, Xiancheng Wu et al. 

Smartphone epifluorescence microscopy for cellular imaging of fresh tissue in low-resource settings (Link)

Wenbin Zhu, Giacomo Pirovano, Patrick K. O’Neal, et al. 

Biomedical Optics Express, 2020, 11, 89-98.

Poly(ADP-ribose)polymerase1: A potential molecular marker to identify cancer during colposcopy procedures (Link)

Paula Demétrio de Souza França, Navjot Guru, Abigail R. Kostolansky, et al. 

Journal of Nuclear Medicine, 2021, 62, 941-948.

Nanoemulsion-based delivery of fluorescent PARP inhibitors in mouse models of small cell lung cancer (Link)

Junior Gonzales, Susanne Kossatz, Sheryl Roberts, et al. 

Bioconjugate Chem, 2018, 29, 3776–3782.

Brandon Carney, Susanne Kossatz, Thomas Reiner, et al. 

Journal of Nuclear Medicine, 2016, 58, 1025-1030.

Effect of small-molecule modification on single-cell pharmacokinetics of PARP inhibitors (Link)

Brandon Carney, Susanne Kossatz and Thomas Reiner, et al. 

Molecular Cancer Therapeutics, 2014, 13, 986-995.

PARPi-FL - a fluorescent PARP1 inhibitor for glioblastoma imaging (Link)

Christopher P. Irwin, Yasiri Portorreal, Christian Brand, et al. 

Neoplasia, 2014, 5, 432-440.

Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo (Link)

Greg M. Thurber, Katy S. Yang, Thomas Reiner, et al. 

Nature Communications, 2013, 4, 1504.

Imaging therapeutic PARP inhibition in vivo through bioorthogonally developed companion imaging agents (Link)

Thomas Reiner, Jessica Lacy, Edmund J. Keliher, et al. 

Neoplasia, 2012, 14, 169-170.